Navigating current treatment options for HER2-positive MBC: Patient journey 1

Bookmark and Share
Published: 18 Sep 2014
Views: 3155
Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria

EBCC 2014 Satellite Symposium supported by GSK: 'Heading in the right direction? Optimal sequencing pathways for HER2-positive metastatic breast cancer'

Prof Bartsch talks through the options available for HER2-positive metastatic breast cancer for a certain case study.

To view the slides fullscreen click the square and arrows button at the bottom right of the player.

GSK has paid for the organisational costs of the symposium, and honoraria for the chairperson and speakers. GSK has contributed to the agenda and content of this meeting.